195 related articles for article (PubMed ID: 12705636)
1. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
Zhang H; Yano S; Miki T; Goto H; Kanematsu T; Muguruma H; Uehara H; Sone S
Clin Exp Metastasis; 2003; 20(2):153-9. PubMed ID: 12705636
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid hormone-related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC-5 cells in natural killer cell-depleted SCID mice.
Miki T; Yano S; Hanibuchi M; Kanematsu T; Muguruma H; Sone S
Int J Cancer; 2004 Feb; 108(4):511-5. PubMed ID: 14696114
[TBL] [Abstract][Full Text] [Related]
4. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice.
Miki T; Yano S; Hanibuchi M; Sone S
Oncol Res; 2000; 12(5):209-17. PubMed ID: 11417746
[TBL] [Abstract][Full Text] [Related]
5. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567
[TBL] [Abstract][Full Text] [Related]
6. Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity.
Muguruma H; Yano S; Kakiuchi S; Uehara H; Kawatani M; Osada H; Sone S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8822-8. PubMed ID: 16361571
[TBL] [Abstract][Full Text] [Related]
7. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
[TBL] [Abstract][Full Text] [Related]
8. A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.
Otsuka S; Hanibuchi M; Ikuta K; Yano S; Goto H; Ogino H; Yamada T; Kakiuchi S; Nishioka Y; Takahashi T; Sone S
Oncol Res; 2009; 17(11-12):581-91. PubMed ID: 19806789
[TBL] [Abstract][Full Text] [Related]
9. Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Yamada T; Muguruma H; Yano S; Ikuta K; Ogino H; Kakiuchi S; Hanibuchi M; Uehara H; Nishioka Y; Sone S
Mol Cancer Ther; 2009 Jan; 8(1):119-26. PubMed ID: 19139120
[TBL] [Abstract][Full Text] [Related]
10. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.
Sato K; Yuasa T; Nogawa M; Kimura S; Segawa H; Yokota A; Maekawa T
Br J Cancer; 2006 Nov; 95(10):1354-61. PubMed ID: 17043684
[TBL] [Abstract][Full Text] [Related]
11. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
Yuasa T; Nogawa M; Kimura S; Yokota A; Sato K; Segawa H; Kuroda J; Maekawa T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):853-9. PubMed ID: 15701876
[TBL] [Abstract][Full Text] [Related]
12. Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.
Kurabayashi A; Inoue K; Fukuhara H; Karashima T; Fukata S; Kawada C; Shuin T; Furihata M
Cancer Sci; 2015 Aug; 106(8):1092-9. PubMed ID: 26041278
[TBL] [Abstract][Full Text] [Related]
13. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
Sasaki A; Kitamura K; Alcalde RE; Tanaka T; Suzuki A; Etoh Y; Matsumura T
Int J Cancer; 1998 Jul; 77(2):279-85. PubMed ID: 9650565
[TBL] [Abstract][Full Text] [Related]
14. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of multiorgan metastases of human lung cancer cells genetically engineered to produce cytokines and reversal using chimeric monoclonal antibodies in natural killer cell-depleted severe combined immunodeficient mice.
Sone S; Yano S; Hanibuchi M; Nokihara H; Nishimura N; Miki T; Nishioka Y; Shinohara T
Cancer Chemother Pharmacol; 1999; 43 Suppl():S26-31. PubMed ID: 10357555
[TBL] [Abstract][Full Text] [Related]
16. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
[TBL] [Abstract][Full Text] [Related]
17. Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice.
Sakaguchi S; Goto H; Hanibuchi M; Otsuka S; Ogino H; Kakiuchi S; Uehara H; Yano S; Nishioka Y; Sone S
Clin Exp Metastasis; 2010 May; 27(5):351-9. PubMed ID: 20464627
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
Koshimune R; Aoe M; Toyooka S; Hara F; Ouchida M; Tokumo M; Sano Y; Date H; Shimizu N
BMC Cancer; 2007 Jan; 7():8. PubMed ID: 17222343
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
[TBL] [Abstract][Full Text] [Related]
20. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells.
Nokihara H; Yano S; Nishioka Y; Hanibuchi M; Higasida T; Tsuruo T; Sone S
Jpn J Cancer Res; 2001 Jul; 92(7):785-92. PubMed ID: 11473730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
